• compact-technology

    Oval’s technology allows for a compact, portable, ergonomic design

    Simple two-step operation and provides patient feedback at every step

  • patient-usability

    Oval’s device offers adaptable external features enabling superior patient usability and preference

    Work with our Industrial Design team to create a device to suit your patient population …

Latest News…

Oval and SOLIZE enter into collaboration on injection device development

Press Release   For Immediate Release Cambridge, UK. Monday, 28 April 2014 – Oval Medical Technologies Limited (“Oval”) Oval and SOLIZE enter into collaboration on injection device development. Working together to accelerate product development in the growing auto-injector market. Oval Medical Technologies Ltd (Cambridge, UK) and SOLIZE Corporation (Tokyo, Japan) have agreed to collaborate together […]

Continue Reading

Technology Strategy Board – Smart Funding Award

Press Release For Immediate Release Oval Medical awarded Technology Strategy Board Smart funding award Cambridge, UK. 14 April 2014 – Oval Medical Technologies Limited (“Oval”) announced today they have received a Smart funding award from the UK’s innovation agency, the Technology Strategy Board, of £228,256 for a project that will progress the development of the […]

Continue Reading

Oval Medical announces new Chairman of the Board

Oval Medical Technologies Limited (“Oval”), a leading auto-injector company, has named Dr. Paul Harper as Chairman of the Board. He will be succeeding Peter Keen after his three-year tenure.  Peter has now taken the position of Chief Executive at investment fund Cambridge Innovation Capital. Dr Harper took up the role at Oval in January 2014, […]

Continue Reading

Oval Medical secures £1 million deal with US pharmaceutical company

Oval Medical Technologies Ltd (‘Oval’) today announced that they have signed another deal following an initial feasibility study with a global pharmaceutical company, to a value in excess of one million pounds. The feasibility study, which primarily focused on the pharmaceutical drug’s stability in Oval’s standard primary drug container, started in March 2012 and completed […]

Continue Reading